04/03/2015 07:46:59 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
03/03/20156:28AMSEEK10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
http://seekingalpha.com/article/2967816-10-dandy-dividend-healthcare-dogs-hail-14-percent-february-upsides?source=partner_advfn More...>>
03/02/20158:00AMBWMerck to Present at the 35th Annual Cowen Health Care Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the 35th Annual Cowen Health Care Conference in Boston on Mar. 3, 2015 at 8:40 a.m. EST. Investors, analysts, members of... More...>>
03/01/20155:02AMSEEKSome Companies Are More Wonderful Than Others
http://seekingalpha.com/article/2961956-some-companies-are-more-wonderful-than-others?source=partner_advfn More...>>
02/26/20153:18PMBWMerck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to include GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in the recommendations for use... More...>>
02/26/20156:22AMDJNBayer Reiterates Plans to Divest Plastics Business -- 2nd Update
By Christopher Alessi LEVERKUSEN, Germany--German pharmaceutical group Bayer AG reiterated on Thursday plans to divest itself of its high-tech plastics business, saying it would legally and economically separate the Material Science division by the end of August. "In the second half of this year, we intend to decide which... More...>>
02/26/20154:15AMDJNBayer Profit Falls Sharply as Costs Bite --Update
By Christopher Alessi LEVERKUSEN, Germany-- Bayer AG on Thursday posted a 51% drop in net profit for the fourth quarter of 2014, weighed down by higher research and development and selling costs. The German pharmaceutical group said net profit for the three-month period ended Dec. 31 was EUR224 million ($254 million... More...>>
02/26/20152:24AMDJNBayer Profit Falls Sharply as Costs Bite
By Christopher Alessi LEVERKUSEN, Germany-- Bayer AG on Thursday posted a 51% drop in net profit for the fourth quarter of 2014, weighed down by higher research and development and selling costs. The German pharmaceutical group said net profit for the three-month period ended Dec. 31 was EUR224 million ($254 million... More...>>
02/25/20156:15PMDJNGeneric Copies of Remicade Go on Sale in Europe
By Peter Loftus Generic-drug makers have begun selling lower-priced copies of the blockbuster anti-inflammatory drug Remicade throughout Europe in recent days, a milestone in the emerging market for so-called "biosimilars," or generic versions of complex biotechnology drugs. An approaching wave of biosimilars in Europe... More...>>
02/25/20158:00AMBWNew Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) & TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be...
Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the company’s cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual... More...>>
02/24/201512:51PMBWMerck Announces Second-Quarter 2015 Dividend
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the company’s common stock for the second quarter of 2015. Payment will be made on Apr. 8, 2015, to stockholders of record at the close of business on... More...>>
02/24/20153:00AMBWMerck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Dev...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an agreement with the Medicines Patent Pool (MPP) to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children from four weeks to under 12 years of age in developing countries. This is... More...>>
02/23/20156:22PMBWMerck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist’s 2.50...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the “Convertible Notes Tender Offer”) pursuant to which each holder of Cubist’s 2.50% Convertible Senior Notes due 2017 (the... More...>>
02/23/20155:03PMBWMerck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist’s 2.50...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the “Convertible Notes Tender Offer”) pursuant to which each holder of Cubist’s 2.50% Convertible Senior Notes due 2017 (the... More...>>
02/23/20151:26PMDJNMerck to Team With NGM to Develop Diabetes and Obesity Treatments -- Update
By Angela Chen Merck & Co. Inc. said Monday that it has entered a five-year collaboration with NGM Biopharmaceuticals Inc. to research and develop drugs that treat diabetes and obesity, in the drug company's latest bid to introduce new products. Merck will pay NGM $95 million and buy a 15% equity stake for $106 million... More...>>
02/23/20151:21PMDJNMerck to Team With NGM to Develop Diabetes Treatment
By Angela Chen Merck & Co. Inc. said Monday that it has entered a five-year collaboration with NGM Biopharmaceuticals Inc. to research and develop drugs that treat diabetes and obesity, in the drug company's latest bid to introduce new products. Merck will pay NGM $95 million and buy a 15% equity stake for $106 million... More...>>
02/23/20157:00AMBWNGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
Partnership Combines NGM’s Unique Biology-focused Research Platform with Merck’s Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada... More...>>
02/20/201511:04AMDJNFormer Merck Analyst Pleads Guilty to Insider Trading Charges
By Michael Calia A former financial analyst for pharmaceutical giant Merck & Co. Inc. this week pleaded guilty to charges related to insider trading, authorities said. Zachary Zwerko, 32 years old, pleaded guilty to one count of conspiracy to commit securities fraud and three counts of securities fraud stemming from... More...>>
02/19/20158:30AMGLOBENewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola Vaccine Candidate
AMES, Iowa, Feb. 19, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it had received notification from Merck (NYSE:MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV (Ebola... More...>>
02/09/20157:00PMDJNMicrosoft's Bond Sale Is Largest of the Year -- Update
By Mike Cherney Microsoft Corp. is outshining Apple Inc. in at least one area: bond sales. The software giant on Monday completed the largest U.S. corporate-bond sale this year, selling $10.75 billion in debt with maturities of five to 40 years. The sale surpasses a pair of megabonds issued last week, an $8 billion sale... More...>>
02/09/20154:49PMDJNMicrosoft's Bond Sale Is Largest of the Year
By Mike Cherney Microsoft Corp. is outshining Apple Inc. in at least one area: the bond market. Microsoft on Monday is selling $10.75 billion in new bonds, making it this year's largest U.S. corporate debt sale, following Apple Inc.'s $6.5 billion deal last week. Reflecting good demand for its bonds, Microsoft--one of... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150304 07:46